Gain Therapeutics Faces Delisting Concerns
Ticker: GANX · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $50 million |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Gain Therapeutics might be delisted, stock alert!
AI Summary
Gain Therapeutics, Inc. filed an 8-K on January 15, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The earliest event reported was January 8, 2025. The company is incorporated in Delaware and its principal executive offices are located in Bethesda, Maryland.
Why It Matters
This filing indicates potential issues with Gain Therapeutics' continued listing on an exchange, which could significantly impact its stock price and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial stability.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- January 8, 2025 (date) — Earliest event reported
- January 15, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Bethesda, Maryland (location) — Principal executive offices
FAQ
What specific listing rule or standard has Gain Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Gain Therapeutics has failed to satisfy, only that a notice has been issued.
What is the reason for the potential transfer of listing?
The filing indicates a 'Transfer of Listing' as part of the notice, but the specific reasons or destination exchange are not detailed in this initial report.
When was the earliest event reported that led to this notice?
The earliest event reported in this filing occurred on January 8, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 85-1726410.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-01-15 17:00:21
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GANX The Nasdaq
- $50 million — ities ("MVLS") was below the minimum of $50 million required for continued listing on The N
Filing Documents
- tm253348d1_8k.htm (8-K) — 25KB
- 0001104659-25-003801.txt ( ) — 197KB
- ganx-20250108.xsd (EX-101.SCH) — 3KB
- ganx-20250108_lab.xml (EX-101.LAB) — 33KB
- ganx-20250108_pre.xml (EX-101.PRE) — 22KB
- tm253348d1_8k_htm.xml (XML) — 4KB
01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. On January 8, 2025, Gain Therapeutics Inc. (the "Company") received a letter (the "MVLS Deficiency Notice") from the listing qualifications department staff (the "Staff") of The Nasdaq Stock Market ("Nasdaq") notifying the Company that that from November 14, 2024 to December 27, 2024, the Company's Market Value of Listed Securities ("MVLS") was below the minimum of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Requirement"). The MVLS Deficiency Notice had no immediate effect on the listing of the Company's common stock, and the Company's common stock continues to trade on the Nasdaq Global Market under the symbol "GANX." As of January 14, 2025, the Company has regained compliance with the MVLS Requirement and the Staff has provided written confirmation of compliance on January 15, 2025. The matter is now closed. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 15, 2025 GAIN THERAPEUTICS, INC. By: /s/ Gene Mack Name: Gene Mack Title: Chief Executive Officer 2